Genomma Lab Internacional, S.A.B. De C.V. Reports Earnings Results for the Third Quarter Ended September 30, 2020
October 21, 2020 at 01:17 am EDT
Share
Genomma Lab Internacional, S.A.B. De C.V. Announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced sales was MXN 3,427.909 million compared to MXN 3,077.305 million a year ago. Net income was MXN 409.136 million compared to MXN 233.387 million a year ago. For the nine months, sales was MXN 10,398.770 million compared to MXN 9,492.619 million a year ago. Net income was MXN 1,143.587 million compared to MXN 728.823 million a year ago.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Companyâs product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. 
